摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-{[4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]methyl}phenyl)-3-phenyl-1,6-naphthyridin-5(6H)-one | 893422-48-5

中文名称
——
中文别名
——
英文名称
2-(4-{[4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]methyl}phenyl)-3-phenyl-1,6-naphthyridin-5(6H)-one
英文别名
2-[4-[[4-(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]methyl]phenyl]-3-phenyl-6H-1,6-naphthyridin-5-one
2-(4-{[4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]methyl}phenyl)-3-phenyl-1,6-naphthyridin-5(6H)-one化学式
CAS
893422-48-5
化学式
C31H28N8O
mdl
——
分子量
528.616
InChiKey
VVBRZLYZDJRPJI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    40
  • 可旋转键数:
    5
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    115
  • 氢给体数:
    2
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • Inhibitors of Akt Activity
    申请人:Arruda Jeannie M.
    公开号:US20080287457A1
    公开(公告)日:2008-11-20
    The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.
    本发明涉及含有取代萘啶的化合物,其抑制Akt蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物以及治疗癌症的方法,包括给予本发明化合物的治疗方法。这些取代萘啶与PCT出版物WO2003/086394中报告的其他萘啶相比具有意外的优点,这些意外的优点可能包括增强的细胞效力/溶解度、更大的选择性、增强的药代动力学性质、缺乏非靶标活性等。
  • Inhibitors of Akt activity
    申请人:Merck Sharp & Dohme Corp.
    公开号:US07910561B2
    公开(公告)日:2011-03-22
    The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.
    本发明涉及含有取代萘啶的化合物,其能够抑制Akt酶的活性,Akt酶是一种丝氨酸/苏氨酸蛋白激酶。本发明还涉及包含本发明化合物的化疗组合物以及治疗癌症的方法,包括给予本发明化合物的治疗。与PCT出版物WO2003/086394中报道的其他萘啶相比,这些取代萘啶具有意外的优势特性,这些意外的优势特性可能包括增加的细胞效力/溶解度,更强的选择性,增强的药代动力学特性,缺乏非特异性作用等。
  • INHIBITORS OF AKT ACTIVITY
    申请人:Merck & Co., Inc.
    公开号:EP1827436A2
    公开(公告)日:2007-09-05
  • USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
    申请人:DelMar Pharmaceuticals, Inc.
    公开号:US20180071244A1
    公开(公告)日:2018-03-15
    The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
  • US7910561B2
    申请人:——
    公开号:US7910561B2
    公开(公告)日:2011-03-22
查看更多